YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cybersecurity solutions provider, acknowledged the disclosure by ZenaTech, Inc. ("Z…
We just covered the 7 Best Lab-Grown Meat Stocks to Invest In and Pluri Inc. (NASDAQ:PLUR) ranks 4th on this list. Pluri Inc. (NASDAQ:PLUR), through the highly publicized joint venture, Ever After Foods, utilizes proprietary, state-of-the-…
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executi…
Pluri Inc. (NASDAQ:PLUR) is one of the best long term penny stocks with huge upside potential. On October 8, Pluri announced that its wholly-owned subsidiary, Coffeesai Ltd., had signed a collaboration agreement with the Instituto del Café…
Former Raytheon and Booz Allen Executive to Lead Margin Expansion Strategy Vancouver, British Columbia--(Newsfile Corp. - October 1, 2025) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cyber…
* Pluri (NASDAQ:PLUR [https://seekingalpha.com/symbol/PLUR]) filed to sell 3.425M common shares for holders. * Filing [https://seekingalpha.com/filing/10427363] MORE ON PLURI INC. * Seeking Alpha’s Quant Rating on Pluri Inc. [https://seeki…
Plurilock Security Inc. reported its earnings for Q2 2025, showcasing a 15% year-over-year increase in total revenue, reaching $16.4 million. Despite a downturn in gross margin, the company’s strategic focus on high-value sectors and servi…
Pluri Inc. (NASDAQ:PLUR) announced Thursday that director Doron Birger was not re-elected to the company’s board at its annual shareholder meeting held Monday. As a result, Birger, who was an independent director, chairman of the audit com…
Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of DirectorsPluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on…
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of Health PLX-R18 has the advantage of being an off-the-shelf product wi…
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced t…
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident. The work specified by the contractis based on communications with the FDA and w…
Breakthrough systemsubstantially increases cell production,with the potential to reach much higher productivitydriven by platform’s significant scalability Flexible, industrial scale cell production to power a broad range of cell-based pro…
HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, announced today that Israel’s Ministry o…
Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership; Joint venture with Tnuvareaches proof of concept and cont…
HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities purchase agreements with domestic and non-U.…
HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, won Cell Innovation award in the Cell Biol…
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three…
New companystrategy will reduce cash burn by approximately30%, with $56M in cash on consolidated balance sheetLeading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s 3D cell expansion technology, which aims…
HAIFA, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced that a €7.5 million non-…
Pluristem Therapeutics, Inc. HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued…
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholder…
As ofJuly 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various li…
Pluristem Therapeutics, Inc. Pluri Inc. logo WHERE TECHNOLOGY COMES TO LIFE As ofJuly 26, 2022, Pluri’s stock will trade under the symbol PLUR The new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology…